Concord Biotech Limited vs Cohance Lifesciences Limited
Last updated: 20 October 2026
Concord Biotech Limited vs Cohance Lifesciences Limited: A MoneyDock Comparison
In the dynamic Indian pharmaceutical and biotechnology sector, investors often seek opportunities among specialized players. This comparison article from MoneyDock pits two such entities against each other: Concord Biotech Limited (CONCORDBIO.NS) and Cohance Lifesciences Limited (COHANCE.NS). While specific details of their core operations are not provided in the given data, both companies operate within the broader life sciences domain, making a comparative analysis of their market performance, valuation metrics, and stock stability highly relevant for potential investors. This analysis will delve into their recent stock performance, current prices, and key financial indicators to help investors make informed decisions.
Key Financial Metrics Comparison
| Metric | Concord Biotech Limited (CONCORDBIO.NS) | Cohance Lifesciences Limited (COHANCE.NS) |
|---|---|---|
| Current Price | ₹1285.80 | ₹457.70 |
| 52W High | ₹1579.40 | ₹539.85 |
| 52W Low | ₹1014.80 | ₹279.90 |
| 1-Year Return | -6.13% | -14.58% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Valuation, Returns, and Stability
When evaluating Concord Biotech and Cohance Lifesciences, the absence of Trailing P/E and Market Cap data makes a direct valuation comparison challenging. However, we can still glean insights from their stock performance. In terms of current price, Concord Biotech is significantly higher at ₹1285.80 compared to Cohance Lifesciences' ₹457.70. This simply indicates a higher nominal share price, not necessarily a higher valuation.
Looking at returns, both companies have posted negative 1-year returns, indicating a challenging period for both in the past year. Concord Biotech shows a 1-year return of -6.13%, which, while negative, is considerably better than Cohance Lifesciences' -14.58%. This suggests that Concord Biotech has weathered the market downturn or specific sector headwinds more effectively than Cohance Lifesciences over the past 12 months, indicating stronger relative performance in terms of returns.
For stability, we can look at the proximity of their current price to their 52-week high and low. Concord Biotech's current price of ₹1285.80 is closer to its 52-week high of ₹1579.40 than its 52-week low of ₹1014.80. Specifically, it's about 81% of its 52-week high and approximately 26% above its 52-week low. Cohance Lifesciences, with a current price of ₹457.70, is also closer to its 52-week high of ₹539.85 (about 85%) and approximately 63% above its 52-week low of ₹279.90. While both are off their highs, Cohance Lifesciences has experienced a larger percentage swing from its 52-week low, suggesting potentially higher volatility or a more significant recovery from its trough. Concord Biotech appears to have maintained a somewhat tighter range relative to its 52-week extremes, potentially implying greater price stability.
MoneyDock Verdict
For Aggressive Investors: Given the higher percentage return over the last year (less negative) and potentially tighter trading range, Concord Biotech Limited might be perceived as having slightly better momentum and resilience in the recent past. However, aggressive investors might also be drawn to Cohance Lifesciences if they believe its larger drop presents a greater rebound opportunity, assuming a turnaround.
For Conservative Investors: Based purely on the 1-year return, Concord Biotech Limited appears to be the less risky option, having incurred a smaller loss over the past year. Its higher current price relative to its 52-week low might also suggest a more established price floor compared to Cohance Lifesciences, which has seen a larger percentage increase from its low, potentially indicating higher volatility or recovery risk.
For Long-Term SIP Investors: Without P/E and Market Cap data, long-term investors must look beyond short-term price movements. However, if forced to choose based on these limited metrics, Concord Biotech Limited seems to have demonstrated slightly better stock performance stability and less severe negative returns. For SIP investors, consistent performance, even if moderately negative, is often preferred over larger swings. Both require deeper fundamental analysis, which is beyond the scope of the provided data, to assess their long-term growth prospects.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.